Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
leggi di più
leggi meno
10 anni fa
#acquired, #alk, #alkpositive, #ap26113, #cancergrace, #ch5424802, #david, #dr, #edward, #garon, #geffen, #grace, #gracecast, #ldk378, #medicine, #of, #rearrangement, #resistance, #school, #ucla
